Chromocell Therapeutics (CHRO) versus Its Rivals Financial Contrast

Chromocell Therapeutics (NYSE:CHRO) is one of 300 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare Chromocell Therapeutics to similar businesses based on the strength of its profitability, risk, institutional ownership, analyst recommendations, valuation, dividends and earnings.

Insider & Institutional Ownership

78.0% of Chromocell Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 16.4% of Chromocell Therapeutics shares are owned by insiders. Comparatively, 15.8% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Chromocell Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Chromocell Therapeutics	N/A	-$7.38 million	-0.73
Chromocell Therapeutics Competitors	$583.57 million	-$70.96 million	3.99

Chromocell Therapeutics’ rivals have higher revenue, but lower earnings than Chromocell Therapeutics. Chromocell Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Chromocell Therapeutics has a beta of 4.59, indicating that its share price is 359% more volatile than the S&P 500. Comparatively, Chromocell Therapeutics’ rivals have a beta of -4.57, indicating that their average share price is 557% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Chromocell Therapeutics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chromocell Therapeutics	0	0	1	0	3.00
Chromocell Therapeutics Competitors	1999	5510	14177	309	2.58

As a group, “Biological products, except diagnostic” companies have a potential upside of 132.76%. Given Chromocell Therapeutics’ rivals higher probable upside, analysts clearly believe Chromocell Therapeutics has less favorable growth aspects than its rivals.

Profitability

This table compares Chromocell Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Chromocell Therapeutics	N/A	N/A	-453.90%
Chromocell Therapeutics Competitors	-2,185.76%	-161.46%	-40.62%

Summary

Chromocell Therapeutics beats its rivals on 8 of the 13 factors compared.

About Chromocell Therapeutics

Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.